# Open-label Comparison of 24hr Gastric pH on Days 1, 2, 7 With Once-daily Administration of Lavoltidine 40 mg.

> **NCT00551473** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 18 (actual)

## Conditions studied

- Gastroesophageal Reflux Disease
- Reflux, Gastroesophageal

## Interventions

- **DRUG:** Lavoltidine

## Key facts

- **NCT ID:** NCT00551473
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-05
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2012-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00551473

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00551473, "Open-label Comparison of 24hr Gastric pH on Days 1, 2, 7 With Once-daily Administration of Lavoltidine 40 mg.". Retrieved via AI Analytics 2026-09-22 from https://api.ai-analytics.org/clinical/NCT00551473. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*